目录产品 » IL-19 hFc Chimera, Human
Manual
SDS
COAs

IL-19 hFc Chimera, Human

Interleukin-19 (IL-19) has been shown to be involved in coronary artery diseases and atherosclerosis, while its expression in myocardial infarction is poorly understood. In this study, the dynamic increase in circulating IL-19 in acute ST-segment elevation myocardial infarction (STEMI) patients was detected.IL-19 is correlated with the severity of acute myocardial infarction, which may be a new idea for the clinical treatment of myocardial infarction.
￥3000
Z05457-100

产品简介
Species Human
Protein Construction
IL-19 (Leu25-Ala177)_x000D_
Accession # Q9UHD0-1		 hFc
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
Endotoxin Level Less than 1EU per μg by the LAL method.
Expression System HEK293
Theoretical Molecular Weight 44.6 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 55-60 kDa based on Bis-Tris PAGE result.
Formulation Supplied as 0.22μm filtered solution in 20mM Tris, 500mM NaCl (pH 8.0).
Concentration Verified by one or more methods from 0.64mg/ml A280/Bioactivity/BCA/Bradford.
Storage & Stability This product remains stable for 6 months at -80°C or below. Avoid repeated freeze-thaw cycles.
返回

技术背景
Target Background Interleukin-19 (IL-19) has been shown to be involved in coronary artery diseases and atherosclerosis, while its expression in myocardial infarction is poorly understood. In this study, the dynamic increase in circulating IL-19 in acute ST-segment elevation myocardial infarction (STEMI) patients was detected.IL-19 is correlated with the severity of acute myocardial infarction, which may be a new idea for the clinical treatment of myocardial infarction.
Synonyms Interleukin-19; IL-19; ZMDA1; IL-10C; MDA1; NG.1
返回

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.